Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics

Aimmune Therapeutics logoAimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AIMT
  • CUSIP:
Key Metrics:
  • Previous Close: $19.57
  • 50 Day Moving Average: $19.42
  • 200 Day Moving Average: $18.62
  • 52-Week Range: $9.77 - $27.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.09
  • P/E Growth: 0.25
  • Market Cap: $827.72M
  • Outstanding Shares: 42,382,000
  • Beta: -1.23
Profitability:
  • Return on Equity: -132.42%
  • Return on Assets: -37.19%
Debt:
  • Current Ratio: 12.89%
  • Quick Ratio: 12.89%
Additional Links:
Companies Related to Aimmune Therapeutics:

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.75 (87.21% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetDetails
2/19/2017Piper Jaffray CompaniesReiterated RatingOverweight$40.00View Rating Details
2/17/2017WedbushReiterated RatingOutperform$42.00View Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details
8/19/2016Credit Suisse GroupReiterated RatingBuy$35.00View Rating Details
5/16/2016Bank of America CorpReiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
11/14/2016Q3 2016($0.45)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
Current Year EPS Consensus Estimate: $-1.81 EPS
Next Year EPS Consensus Estimate: $-2.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.46)($0.46)($0.46)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.52)($0.52)($0.52)
Q4 20171($0.54)($0.54)($0.54)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 61.61%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.60View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.00View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.00View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
DateHeadline
News IconAimmune Therapeutics Inc. (NASDAQ:AIMT) is Attracting Smart Money - Small Cap Exclusive (press release) (NASDAQ:AIMT)
smallcapexclusive.com - February 22 at 11:39 AM
News IconStock Spotlight: Zooming in on Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - BVN (NASDAQ:AIMT)
bvnewsjournal.com - February 21 at 3:40 PM
News IconStock Tracker: Trend Analysis on Aimmune Therapeutics Inc (AIMT) - Baldwin Journal (NASDAQ:AIMT)
baldwinjournal.com - February 18 at 9:35 AM
streetinsider.com logoAimmune Therapeutics (AIMT) Offers Update on Ongoing AR101 Phase 3 Program for Peanut Allergy - StreetInsider.com (NASDAQ:AIMT)
www.streetinsider.com - February 18 at 9:35 AM
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $40 PT on Aimmune Therapeutics (AIMT) Following AR101 Update - StreetInsider.com (NASDAQ:AIMT)
www.streetinsider.com - February 18 at 9:35 AM
streetinsider.com logoAimmune Therapeutics (AIMT) Offers Update on Ongoing AR101 Phase 3 Program for Peanut Allergy (NASDAQ:AIMT)
www.streetinsider.com - February 16 at 8:33 PM
finance.yahoo.com logoAimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
finance.yahoo.com logoAimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
finance.yahoo.com logoAimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
finance.yahoo.com logo4:02 pm Aimmune Therapeutics announces recent feedback from FDA; BLA Filing Expected to Include Safety Data on 600 Patients Treated with AR101 (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
finance.yahoo.com logo4:02 pm Aimmune Therapeutics announces recent feedback from FDA; BLA Filing Expected to Include Safety Data on 600 Patients Treated with AR101 (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
finance.yahoo.com logo4:02 pm Aimmune Therapeutics announces recent feedback from FDA; BLA Filing Expected to Include Safety Data on 600 Patients Treated with AR101 (NASDAQ:AIMT)
finance.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAimmune Therapeutics Inc Conference Call to Discuss The Announced AR101 Program Updates scheduled for 5:00 pm ET today (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAimmune Therapeutics Inc Conference Call to Discuss The Announced AR101 Program Updates scheduled for 5:00 pm ET today (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
biz.yahoo.com logoAimmune Therapeutics Inc Conference Call to Discuss The Announced AR101 Program Updates scheduled for 5:00 pm ET today (NASDAQ:AIMT)
biz.yahoo.com - February 16 at 8:33 PM
News IconTrading Watch: Checking in on Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Piedmont Register (NASDAQ:AIMT)
piedmontregister.com - February 14 at 3:41 PM
News IconAimmune Therapeutics, Inc. (AIMT) stock slips, “Overweight” rating reiterated by Piper Jaffray Companies Analysts - The Ledger Gazette (NASDAQ:AIMT)
ledgergazette.com - February 14 at 3:41 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:AIMT)
biz.yahoo.com - February 8 at 3:30 PM
News IconAimmune Therapeutics Inc AIMT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:AIMT)
www.bioportfolio.com - February 7 at 1:32 AM
News IconUpside Alert: Delving into Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Prospect Journal (NASDAQ:AIMT)
prospectjournal.com - January 30 at 8:37 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Aimmune Therapeutics Inc (AIMT) - Market Point (NASDAQ:AIMT)
mtptnews.com - January 30 at 8:37 PM
News IconStocks Wilt on Friday But Pull Off Positive Week, How Did This One Fare: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Wall Street Beacon (NASDAQ:AIMT)
wsbeacon.com - January 30 at 1:28 AM
News IconStock Volume Ratcheting Up Mid-Session For Genworth Financial, Inc. (NYSE:GNW) (NASDAQ:AIMT)
diy-home-garden.com - January 28 at 3:24 PM
News IconStock Update on Earnings & Estimates for Aimmune Therapeutics Inc (NASDAQ:AIMT) - Aiken Advocate (NASDAQ:AIMT)
aikenadvocate.com - January 27 at 8:35 PM
News IconStock Focus: Watching RSI Levels on Shares of Aimmune Therapeutics Inc (AIMT) - Market Point (NASDAQ:AIMT)
mtptnews.com - January 26 at 3:41 PM
News IconTrading Watch: Checking in on Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - The Tribune (NASDAQ:AIMT)
lakecitytribune.com - January 25 at 3:29 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Prospect Journal (NASDAQ:AIMT)
prospectjournal.com - January 23 at 8:27 PM
News IconFocus on RSI and CCI Levels: Aimmune Therapeutics Inc (AIMT) - Sherwood Daily (NASDAQ:AIMT)
sherwooddaily.com - January 20 at 8:35 PM
News IconFocusing on the Numbers for Aimmune Therapeutics Inc (AIMT) - Rives Journal (NASDAQ:AIMT)
rivesjournal.com - January 20 at 3:34 PM
News IconAimmune Therapeutics Inc. (NASDAQ: AIMT) Rating Reiterated at Wedbush - BNB Daily (blog) (NASDAQ:AIMT)
www.baseball-news-blog.com - January 14 at 1:55 AM
News IconShorts On Watch: Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Could Burn Your Long Portfolio After More ... - Baxley Report (NASDAQ:AIMT)
baxleyreport.com - January 12 at 3:27 PM
seekingalpha.com logo2017: A Transformational Year For Aimmune Therapeutics - Seeking Alpha (NASDAQ:AIMT)
seekingalpha.com - January 11 at 3:41 PM
News IconAre There Catalysts to Propel This Stock Forward: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Prospect Journal (NASDAQ:AIMT)
prospectjournal.com - January 9 at 8:38 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:AIMT)
biz.yahoo.com - January 9 at 3:36 PM
finance.yahoo.com logoAimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:AIMT)
finance.yahoo.com - January 4 at 3:30 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Prospect Journal (NASDAQ:AIMT)
prospectjournal.com - December 27 at 6:39 AM
News IconShares to Watch: Indicator Update on Aimmune Therapeutics Inc (AIMT) - StockTalk Daily (NASDAQ:AIMT)
stocktalkdaily.com - December 21 at 9:29 PM
News IconEquity Rundown: RSI and CCI Check on Aimmune Therapeutics Inc (AIMT) - StockTalk Daily (NASDAQ:AIMT)
stocktalkdaily.com - December 17 at 3:27 PM
News IconInvestor Review: Focusing in on Shares of Aimmune Therapeutics Inc (AIMT) - StockTalk Daily (NASDAQ:AIMT)
stocktalkdaily.com - December 16 at 3:31 PM
News IconF-Score Review on Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - The Business Journal (NASDAQ:AIMT)
belmontbusinessjournal.com - December 15 at 3:47 PM
streetinsider.com logoAimmune Therapeutics (AIMT) CFO to Depart - StreetInsider.com (NASDAQ:AIMT)
www.streetinsider.com - December 15 at 3:47 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:AIMT)
biz.yahoo.com - December 14 at 8:38 PM
News IconShares in the Spotlight: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Marion Business Daily (NASDAQ:AIMT)
marionbusinessdaily.com - December 13 at 3:28 PM
News IconCCI Level Review on Aimmune Therapeutics Inc (AIMT) - StockTalk Daily (NASDAQ:AIMT)
stocktalkdaily.com - December 12 at 3:34 PM
insidermonkey.com logoHedge Funds Aren't Crazy About Aimmune Therapeutics Inc (AIMT) Anymore - Insider Monkey (blog) (NASDAQ:AIMT)
www.insidermonkey.com - December 12 at 6:37 AM
News IconWhat The Charts Are Saying About Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Marion Business Daily (NASDAQ:AIMT)
marionbusinessdaily.com - December 9 at 3:27 PM
News IconInvestor Hub: Checking on the Numbers for Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Marion Business Daily (NASDAQ:AIMT)
marionbusinessdaily.com - December 7 at 3:37 PM

Social

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2017?

5 brokerages have issued 1-year target prices for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $42.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $36.75 in the next year.

When will Aimmune Therapeutics announce their earnings?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

What are analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

  • Piper Jaffray Companies analysts commented, "Aimmune provided an update on its clin/reg plan for AR101 following recent FDA discussions. Specifically, the PALISADE Phase III primary analysis and initial BLA application will now include ages 4-17, but exclude adult patients. We see this change as reducing clinical risk for the trial read-out, while still addressing a broad group of children & teens more broadly vs Aimmune's mindshare competitor. Additionally, the FDA provided BTD-enabled guidance on safety database size (n=600), which is within our expectations and achievable under the current Phase III clinical program with current cash. Together with the change in age range, this refinement reduces clinical & regulatory risk for a 2018 BLA filing and subsequent initial label, in our view. And we still expect a market in adults, potentially following another trial. In advance of up-dosing completion for PALISADE around mid'17 and final data around YE17, we reiterate OW and our $40 PT." (2/13/2017)
  • According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (1/17/2017)

Who owns Aimmune Therapeutics stock?

Aimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nestle Health Science US Holdings, Inc (15.12%), FMR LLC (11.68%), Foresite Capital Management II LLC (9.05%), Explore Holdings LLC (2.00%), Foresite Capital Management III LLC (2.13%) and Vivo Capital LLC (1.80%). Company insiders that own Aimmune Therapeutics stock include Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii, and Mary M Rozenman.

Who sold Aimmune Therapeutics stock? Who is selling Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC and Foresite Capital Management III LLC. Company insiders that have sold Aimmune Therapeutics stock in the last year include Foresite Capital Fund Ii, LP and Mary M Rozenman.

Who bought Aimmune Therapeutics stock? Who is buying Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Employees Retirement System of Texas, State Street Corp, Renaissance Technologies LLC, Russell Investments Group Ltd., Artal Group S.A. and FMR LLC.

How do I buy Aimmune Therapeutics stock?

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aimmune Therapeutics stock cost?

One share of Aimmune Therapeutics stock can currently be purchased for approximately $19.63.

Aimmune Therapeutics (NASDAQ:AIMT) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Earnings History Chart

Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Dividend History Chart

Dividend Payments by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Last Updated on 2/24/2017 by MarketBeat.com Staff